T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication - PubMed
3 hours ago
- #Cathepsin G
- #AML immunotherapy
- #TCR engineering
- T cells engineered with a dual HLA-restricted TCR targeting cathepsin G (CTSG) effectively eradicate AML in vitro and in vivo.
- The TCR recognizes CTSG peptides presented by HLA-A*24:02 and HLA-C*07:02, common HLA alleles, allowing broad applicability across AML subtypes.
- Engineered CD4+ CD8+ T cells show enhanced functionality without altering subset identity and exhibit strong, specific cytotoxicity against primary AML blasts.
- The therapy demonstrates a favorable safety profile with no observed on-target/off-tumor effects or off-target cross-reactivity, preserving normal hematopoiesis and organ function.